Download the full report (116 p.) - KCE

2 Multislice CT in Coronary Heart Disease KCE Reports 82
6.1.2 Multislice Cardiac CT in Belgium................................................................................................49
6.2 REGULATORY ISSUES..............................................................................................................................51
6.2.1 Authorization ..................................................................................................................................51
6.2.2 Planning.............................................................................................................................................51
6.2.3 Financing...........................................................................................................................................51
6.2.4 Patients referral for CT examinations .......................................................................................51
6.3 COVERAGE OF MULTI-SLICE CT ANGIOGRAPHY .......................................................................52
6.3.1 United States of America..............................................................................................................52
6.3.2 Canada..............................................................................................................................................54
6.3.3 Australia ...........................................................................................................................................54
6.3.4 The Netherlands.............................................................................................................................55
6.3.5 France ...............................................................................................................................................55
6.3.6 Germany...........................................................................................................................................55
6.3.7 England..............................................................................................................................................56
6.3.8 Belgium .............................................................................................................................................57
6.4 DISCUSSION...............................................................................................................................................57
7 PATIENT ISSUES.......................................................................................................... 59
7.1 TRUE NEGATIVE TEST RESULT............................................................................................................59
7.2 FALSE NEGATIVE TEST RESULT...........................................................................................................59
7.3 TRUE POSITIVE TEST RESULT...............................................................................................................59
7.4 FALSE POSITIVE TEST RESULT..............................................................................................................60
8 GENERAL DISCUSSION.............................................................................................. 61
8.1 TECHNICAL EFFICACY...........................................................................................................................61
8.2 DIAGNOSTIC ACCURACY....................................................................................................................62
8.3 DIAGNOSTIC THINKING ......................................................................................................................62
8.4 THERAPEUTIC IMPACT ..........................................................................................................................62
8.5 PATIENT OUTCOMES.............................................................................................................................63
8.6 COST-EFFECTIVENESS ............................................................................................................................63
9 CONCLUSIONS ............................................................................................................ 64
9.1 TECHNICAL EFFICACY...........................................................................................................................64
9.2 DIAGNOSTIC ACCURACY....................................................................................................................64
9.3 DIAGNOSTIC THINKING ......................................................................................................................64
9.4 THERAPEUTIC IMPACT ..........................................................................................................................64
9.5 PATIENT OUTCOMES.............................................................................................................................64
9.6 COST-EFFECTIVENESS ............................................................................................................................64
10 APPENDICES................................................................................................................. 65
REFERENCES ........................................................................................................................... 92